Movano Inc. (NASDAQ:MOVE – Get Free Report) CFO Jeremy Cogan sold 28,736 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $20.78, for a total transaction of $597,134.08. Following the completion of the transaction, the chief financial officer directly owned 60,504 shares in the company, valued at $1,257,273.12. This trade represents a 32.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Jeremy Cogan also recently made the following trade(s):
- On Tuesday, January 6th, Jeremy Cogan sold 8,218 shares of Movano stock. The shares were sold at an average price of $7.79, for a total transaction of $64,018.22.
- On Monday, January 5th, Jeremy Cogan sold 1,879 shares of Movano stock. The shares were sold at an average price of $8.35, for a total transaction of $15,689.65.
Movano Stock Performance
Shares of Movano stock opened at $19.07 on Friday. The firm has a fifty day moving average of $9.43 and a two-hundred day moving average of $7.97. The stock has a market capitalization of $15.83 million, a price-to-earnings ratio of -1.76 and a beta of 0.79. Movano Inc. has a 52 week low of $4.67 and a 52 week high of $55.00.
Analyst Ratings Changes
MOVE has been the topic of several recent analyst reports. Wall Street Zen lowered shares of Movano from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Movano in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.
More Movano News
Here are the key news stories impacting Movano this week:
- Positive Sentiment: Short interest dropped ~41% from Dec. 31 to Jan. 15, reducing the pool of bearish bets and lowering one source of selling pressure.
- Positive Sentiment: Technical: shares recently cleared the 200‑day moving average, a common momentum trigger that can attract retail and quant buying. Movano (NASDAQ:MOVE) Shares Pass Above 200-Day Moving Average
- Positive Sentiment: Institutional note — Citadel Advisors reported a new position in Movano (49,262 shares), which can signal professional interest and provide support.
- Neutral Sentiment: Market structure: multiple intraday LULD (limit up/limit down) pauses and trading halts were recorded — indicates volatility but not an underlying fundamental catalyst.
- Neutral Sentiment: Liquidity: today’s volume remains below the stock’s longer‑term average, so price moves may be amplified by lighter trading.
- Negative Sentiment: Insider selling — CEO John Mastrototaro sold 33,069 shares at about $20.80 (≈37% reduction in his stake). SEC filing: CEO Insider Sale Filing
- Negative Sentiment: Insider selling — CFO Jeremy Cogan sold 28,736 shares at about $20.78 (≈32% reduction in his stake). SEC filing: CFO Insider Sale Filing
- Negative Sentiment: Analyst/ratings pressure — WallStreetZen downgraded Movano to a “sell” and Weiss Ratings reiterated a sell view, keeping sentiment skewed among some brokerages. WallStreetZen downgrade
- Negative Sentiment: Fundamentals mixed — last reported quarter showed an EPS beat versus a very low consensus but revenue materially missed expectations and margins remain deeply negative, a longer‑term risk for valuation.
Institutional Investors Weigh In On Movano
An institutional investor recently bought a new position in Movano stock. Citadel Advisors LLC acquired a new stake in Movano Inc. (NASDAQ:MOVE – Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 49,262 shares of the technology company’s stock, valued at approximately $28,000. Citadel Advisors LLC owned approximately 5.94% of Movano at the end of the most recent quarter. Hedge funds and other institutional investors own 16.64% of the company’s stock.
Movano Company Profile
Movano Health, Inc (NASDAQ: MOVE) is a health technology company focused on developing wearable devices for continuous biometric monitoring. The company’s core mission is to provide accessible, real-time health insights through noninvasive sensors, enabling individuals and care teams to track vital signs and physiological trends outside of traditional clinical settings.
Movano’s flagship product is a biometric monitoring ring designed to measure parameters such as heart rate, blood oxygen saturation, skin temperature, and sleep quality.
See Also
- Five stocks we like better than Movano
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- Buy This Stock at 9:30 AM on MONDAY!
- Nvidia CEO Issues Bold Tesla Call
Receive News & Ratings for Movano Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Movano and related companies with MarketBeat.com's FREE daily email newsletter.
